Yes, Zepbound and Mounjaro Are Chemically Identical
Both Zepbound and Mounjaro contain the exact same active ingredient—tirzepatide—with identical molecular structure, formulation, and pharmacokinetics. The only difference between these two products is their FDA-approved indication and brand name 1, 2.
Active Ingredient: Tirzepatide
Both medications contain tirzepatide, which is described as:
- A dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist
- A single molecule engineered from the native GIP sequence
- Contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and a Lys residue at position 20 attached to 1,20-eicosanedioic acid via a linker
- Molecular weight: 4813.53 Da
- Empirical formula: C225H348N48O68
- Half-life: approximately 5 days (116.7 hours) 3, 2
Formulation Details
The FDA drug label confirms both products are formulated identically as:
- Clear, colorless to slightly yellow sterile solution for subcutaneous injection
- Available in the same dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
- Contain identical excipients (sodium chloride, sodium phosphate dibasic heptahydrate, water for injection)
- Same pH range: 6.5 to 7.5
- Same dosing schedule: once-weekly subcutaneous injection 2
The Only Difference: FDA-Approved Indication
Mounjaro was FDA-approved in May 2022 specifically for type 2 diabetes mellitus 1, 4.
Zepbound was FDA-approved in November 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity 1, 5.
Clinical Implications
Since the medications are chemically identical:
- They produce the same physiological effects (glucose lowering, weight reduction, delayed gastric emptying)
- Share the same side effect profile (predominantly gastrointestinal: nausea, vomiting, diarrhea)
- Have identical contraindications and warnings (including medullary thyroid cancer risk, pancreatitis concerns, gallbladder disease risk) 3
- Require the same dosing titration strategy starting at 2.5 mg weekly 3
The distinction is purely regulatory and marketing-based, allowing the manufacturer to position the same drug for two different primary indications with separate insurance coverage pathways.